Patient Community Events

Informational Webinar on Avapritinib Clinical Trial Program for Systemic Mastocytosis

On Thursday, January 25th, The Mastocytosis Society in collaboration with Blueprint Medicines hosted an informational webcast for the SM patient community about avapritinib (formerly known as BLU-285), an investigational medicine for people with advanced SM.

During the webcast, Dr. Andy Boral, Chief Medical Officer of Blueprint Medicines, shared an update on the avapritinib program, including a summary of updated clinical trial results presented at the American Society of Hematology annual meeting on December 10, 2017. Dr. Boral also provided an update on ongoing and planned avapritinib clinical trials for people with advanced and indolent forms of SM.

To listen to a replay of the webinar, click the link below. Patients and families with additional questions can contact Blueprint Medicines at patients@blueprintmedicines.com.

Recorded Informational Webinar on Avapritinib Clinical Trial Program for Systemic Mastocytosis